Personalized Medicine

BioFluidix

The BioSpot CP is designed to realize complex laboratory tasks. Beside the standard BioSpot features like automated droplet volume calibration, aspiration and nozzle wash, nanoliter droplet dispensing, substrate ionizing and many more, the CP features an individual Z positioning per dispense channel. This allows for a multi-dimension addressability of any substrate. 
It's specific application is the parallelization of diagnostic tests in standard well plates and for combinatory chemistry (DoE). 
Get in touch to learn more about the BioSpot® workstation CP 600 at info@biofluidix.com.

BioSpot® workstation CP 600

Analytical Cannabis 

Speaking at the Analytical Cannabis Expo East Online 2020 back in October, Rob Dhoble, Managing Director at Havas ECS discussed a dual regulatory framework path to improve the needs of healthcare and selfcare. 

Abstract: Many Americans utilize OTC remedies in an attempt to fill the Rx affordability gap. In fact, 31% of surveyed adults report that they or a family member have relied upon home remedies or over-the-counter drugs instead of going to see a doctor, and 18% report not filling an Rx due to cost and taking an OTC product instead.
With large populations of individuals living with unmet and poorly met chronic medical needs, and the availability of relatively few FDA approved prescription cannabinoids, each narrowly labeled, and the widespread commercial availability of federally unregulated non-Rx cannabis products and non-intoxicating cannabinoids such as cannabigerol (CBG) and cannabidiol (CBD), our healthcare marketplace urgently requires a dual-path approach to ensure affordability, and market access to quality Rx and quality non-Rx cannabinoids for use under direction of medical professionals, and for use as non-Rx cannabinoids comprising ”selfcare”.   Specifically, a new “brief summary” non-Rx cannabinoid requirement is proposed, uniformly depicted on product packaging and within product advertising, to summarize the presence or absence of:
• independent laboratory assessed listing of product ingredients including CBD, THC, and other cannabinoids; linalool, myrcene, and other terpenes, inert ingredients, and the absence of contaminants
• identification of ingredients as being botanical, synthetic, or bio-synthetic 
• cGMP FDA compliance in manufacturing and packaging, including package expiration
• bioavailability data in how dose/serving size relates to absorption and blood levels

Rx and non-Rx Cannabinoids: A dual path regulatory framework for market access and product quality, to better support the needs of healthcare and selfcare.

CENTOGENE’s New and Improved Whole Exome Sequencing Service

It takes approx. 7 years to diagnose a patient with a rare disease. With NEW CentoXome®, we can turn those years into days – powered by our best-in-class insights based on superior technology, our extensive clinical experience, and wealth of genetic data in rare diseases.

NEW CentoXome - Turning Years Into Days

CELLSFORCELLS (C4C)

Cell-free therapy based on exosomes is witnessing a surge of published scientific papers, a rise of IP and registered clinicals trials, all driven by a swelling avidity among investors to support this transformative nanomedicine approach.

For cell-free treatment to become a reality, they need to overcome the many manufacturing hurdles posed by the large-scale production of purified exosomes.
Cells for Cells, a clinical-stage biotech company, has announced the publication of new data of its OxiumTMEXO cell culture media for increased exosome production in Frontiers in Biotechnology and Bioengineering, a specialized journal of the field. The company is part of REGENERO, the Chilean consortium for regenerative medicine supported by state funding (CORFO). In a head-to-head comparison, OxiumTMEXO outmatched the standard DMEM (starvation protocol) and a commercially available medium for exosome production. OxiumTMEXO allowed different type of cells, including the broadly used mesenchymal stem cells, to increase by 3-folds their particle production. The isolated exosomes expressed the typical pan markers while preserving their functionality both in vitro and in vivo.

Exosome technology: Downsizing Cell Therapy to Nano-Scale

Technology Networks

What is epigenetics and why is it becoming important in research? Learn more in this interview.

Exploring Genetics - Epigenetics

In this interview we speak with Jennifer Doudna about the co-development of CRISPR-Cas9 and winning a Nobel prize.

Exploring Genetics - Gene Editing: Past, Present and Future

How has genetics influenced modern medicine and what opportunities does precision medicine present?

Exploring Genetics - Genomics and Human Health

Wyss Institute for Biologically Inspired Engineering at Harvard University

Despite increasing vaccination rates, new, more-infectious variants of SARS-CoV-2 could prolong the COVID-19 pandemic. Researchers at the Wyss Institute at Harvard University and MIT have created a low-cost, CRISPR-based diagnostic platform that can detect SARS-CoV-2 variants in a patient's saliva without the need for any additional equipment. The team hopes their device will enable more widespread testing of populations for COVID-19, especially in places that lack lab facilities.

For more information, please visit: https://wyss.harvard.edu/news/a-test-that-detects-covid-19-variants-in-your-spit/

Credit: Wyss Institute at Harvard University

miSherlock - Detecting COVID-19 Variants from Saliva

Teach Me in 10

What are viral variants? How and why do they occur? What impact can they have on our body's immune system response? These are pertinent questions right now. For this Teach Me in 10 episode, we're joined by Dr. Sean Elias from the Jenner Institute at the University of Oxford. In just 10 minutes, Dr. Elias provides you with everything you need to know about viral variants and vaccines.

Personalized Medicine

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.